High LDL cholesterol in midlife: the dementia risk factor the 2024 Lancet Commission added

For years, cholesterol was a heart story. In 2024 it became a brain story too: high LDL cholesterol in midlife was one of two factors added to the Lancet Commission's dementia list, taking it from 12 modifiable risk factors to 14. (The other addition was untreated vision loss.) The Commission estimates that around 7% of dementia cases worldwide are attributable to high LDL from about age 40. The likely mechanism is familiar from the rest of your cardiovascular system — LDL damages the small vessels that feed the brain. The honest caveat, which you'll rarely see in a headline: most of this evidence shows association, not proven cause, and no randomized trial has ever tested dementia as its main outcome. What follows is what the evidence supports, and where it runs out.

Does high cholesterol cause dementia?

Not proven to cause it, but high LDL ("bad") cholesterol in midlife is linked to higher dementia risk. The 2024 Lancet Commission lists it as a modifiable risk factor, attributing about 7% of cases to high LDL from around age 40 — an association, not proven cause.

Why cholesterol reaches your brain

LDL — low-density lipoprotein, the "bad" cholesterol — is the particle that carries cholesterol through your bloodstream and deposits it into artery walls. Over years, that build-up narrows and stiffens vessels. Most people know this as the road to heart attack and stroke. What's less widely known is that the same process plays out in the tiny vessels that feed your brain.

Your brain is fed by a dense network of very small arteries and is unusually sensitive to their condition. When those vessels are damaged, the result is reduced blood flow, tiny bleeds and blockages, and injury to the brain's white matter — the wiring connecting regions to each other. That damage is the direct route to vascular dementia, and it's the clearest, best-understood way cholesterol reaches your brain.

There may also be a second thread. Researchers are investigating whether LDL interacts with the processes behind Alzheimer's disease — including the role of APOE, a gene that governs both cholesterol transport and Alzheimer's risk. That overlap is suggestive, but it's genuinely unsettled science: treat it as an open research question rather than an established mechanism.

This is also why cholesterol doesn't act alone. It travels with the other vascular factors, and they compound each other — which is why blood pressure and dementia and blood sugar and dementia tell such a similar story. The old line that what's good for your heart is good for your brain holds up here better than almost anywhere.

What the evidence actually shows

The case for LDL rests on three kinds of evidence, and they're worth separating because they carry different weight:

• Large cohort studies. Long-term studies that measure people's cholesterol and follow them for years consistently link higher midlife LDL to higher later-life dementia risk. One recent cohort measured LDL in more than 950,000 people under 65 and found higher levels associated with more dementia later. A 2025 study of roughly 109,000 matched patients, published in the Journal of Neurology, Neurosurgery & Psychiatry, found that LDL under 70 mg/dL (1.8 mmol/L) was associated with about 26% lower risk of all-cause dementia and 28% lower risk of Alzheimer's-related dementia, compared with LDL above 130 mg/dL (3.4 mmol/L).
• Mendelian randomization. This is the clever one. It uses the gene variants people are born with — which nudge lifelong cholesterol up or down at random, long before any lifestyle choice — as a natural experiment. Because your genes are dealt before you can confound them, this design gets closer to causation than an ordinary cohort. A 2025 analysis in Alzheimer's & Dementia pooling around a million people found that genetically lower cholesterol, via the same targets that cholesterol-lowering drugs act on, tracked with lower dementia risk. Its authors' reading: lowering cholesterol earlier in life likely reduces dementia risk later.
• Statin studies. Meta-analyses of observational data associate statin use with lower dementia risk — one pooling more than nine million people found roughly 17% lower all-cause dementia risk among statin users, and another pooling 35 cohort studies landed in a similar range. This is the weakest leg of the three, for reasons worth being blunt about.

The statin question, honestly

Here is the thing the headlines tend to skip: no randomized controlled trial has ever tested dementia as its primary endpoint. Every statin-and-dementia number you've read comes from observational research — watching what happens to people who happen to be taking statins, not randomly assigning them.

That matters, because observational data is vulnerable to confounding. People who get prescribed a statin and take it faithfully for a decade differ from those who don't in ways that are hard to measure: they see a doctor regularly, follow medical advice, often do other healthy things. Researchers call it the "healthy user" effect, and it can manufacture a benefit that isn't really the drug's. Statistical adjustment helps but can't fully rule it out — the researchers themselves say so, and consistently call for proper randomized trials.

The same 2025 cohort adds a second dose of nuance. Among people already at low LDL, statin users had a further modest reduction in dementia risk — but taking LDL to very low levels, below roughly 30 mg/dL, showed no additional benefit. Lower is not endlessly better, and there is no established LDL target for your brain specifically. Any target you're given is set from your overall cardiovascular risk.

So the fair summary is: the direction of the evidence is encouraging and it's biologically coherent, but the certainty is a notch below what we have for blood pressure, where actual trials exist. That's a reason for honest interest, not for anyone to change their medication based on a blog post.

Know your number — and why midlife is the window

The most useful thing in this entire article is also the simplest: find out what your LDL is. It's a routine blood test — a lipid panel — that any doctor can order, and many people have already had one without ever registering the result.

High cholesterol produces no symptoms whatsoever — no ache, no warning, nothing to notice. You can carry a high LDL for twenty years and feel entirely well while the damage quietly accrues. "I feel fine" is not information about your cholesterol.

And timing matters. The Lancet Commission's estimate is built specifically on LDL measured from around age 40 — midlife, not old age. That's not arbitrary: vascular damage is cumulative, built over decades, and the changes behind dementia can begin long before any symptom appears. The Mendelian randomization work points the same way, suggesting the earlier cholesterol is lowered, the more the brain stands to gain. Your 40s, 50s and 60s are where acting has the most room to matter — a hopeful framing, because it's a window most people are still inside.

What actually helps

If your LDL is high, it's responsive — to everyday changes and, when your clinician judges it appropriate, to medication:

• Shift what's on the plate. Less saturated fat (fatty and processed meat, butter, coconut and palm oil), more fibre, vegetables, legumes, whole grains, nuts and oily fish. A Mediterranean-style pattern is well studied for both heart and brain.
• Move most days. Regular activity nudges LDL down and HDL up, and physical activity is independently one of the best-supported factors for brain health.
• Mind weight, smoking and alcohol. Losing even a modest amount of excess weight improves the lipid picture; stopping smoking helps your vessels directly and is itself on the Lancet list.
• Talk to your clinician about medication — and only your clinician. If a statin or another lipid-lowering drug is prescribed, taking it consistently is what delivers the benefit. Never start, stop, or change a statin on your own. That decision belongs with a professional who knows your full cardiovascular risk, your other conditions and your other medicines. Nothing here is a reason to do anything differently with a prescription.

Cholesterol is one lever among fourteen, and it's rarely the only one worth pulling. If you want the fuller picture of where you stand, start by learning how to check your dementia risk across all the factors — then take what you find to your doctor, who can confirm your numbers and tailor a plan to you.

How we research and review our content →

This article is educational and is not medical advice, diagnosis, or treatment. Studies cited — including the 2024 Lancet Commission, the 2025 Journal of Neurology, Neurosurgery & Psychiatry LDL cohort, Mendelian randomization analyses and observational statin meta-analyses — describe risk factors and associations in general, not Solenna specifically; the statin evidence is observational and cannot establish cause and effect. Solenna does not diagnose, prevent, treat, or cure Alzheimer's disease or any form of dementia; individual results vary and no outcome is guaranteed. Never start, stop, or change a statin or any other medication, and set no cholesterol target, without speaking to a qualified healthcare professional.